Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. - Wikidata - wikimedia - TriplyDB

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

http://www.wikidata.org/entity/Q43287699

about

Alanine-glyoxylate aminotransferase 2 (AGXT2) polymorphisms have considerable impact on methylarginine and β-aminoisobutyrate metabolism in healthy volunteers Asymmetric dimethyarginine as marker and mediator in ischemic stroke Transsulfuration pathway thiols and methylated arginines: the Hunter Community Study Symmetric dimethylarginine as predictor of graft loss and all-cause mortality in renal transplant recipients Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram.Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort.Atrial Fibrillation Is Associated with a Marker of Endothelial Function and Oxidative Stress in Patients with Acute Myocardial Infarction.Symmetric dimethylarginine as a proinflammatory agent in chronic kidney disease Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies Symmetric Dimethylarginine Is Not Associated with Cumulative Inflammatory Load or Classical Cardiovascular Risk Factors in Rheumatoid Arthritis: A 6-Year Follow-Up Study.Association of dimethylarginines and mediators of inflammation after acute ischemic stroke Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.Associations of functional alanine-glyoxylate aminotransferase 2 gene variants with atrial fibrillation and ischemic stroke.Genome-wide association study of L-arginine and dimethylarginines reveals novel metabolic pathway for symmetric dimethylarginine.Asymmetric and symmetric dimethylarginine in adolescents with hyperuricemia.Changes in biomarkers associated with living kidney donation.Potential serum biomarkers in the pathophysiological processes of stroke Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis.Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA).The role of asymmetric and symmetric dimethylarginines in renal disease.Cardioembolic stroke diagnosis using blood biomarkers.The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases.Effects of chronic SDMA infusion on glomerular filtration rate, blood pressure, myocardial function and renal histology in C57BL6/J mice.Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.Serum Asymmetric and Symmetric Dimethylarginine and Morbidity and Mortality in Hemodialysis Patients.In vivo microvascular and macrovascular endothelial function is not associated with circulating dimethylarginines in patients with rheumatoid arthritis: a prospective analysis of the DRACCO cohort.Nitric oxide synthases and atrial fibrillation Metabolomic profiles indicate distinct physiological pathways affected by two loci with major divergent effect on Bos taurus growth and lipid deposition.Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy.Methylated arginines and nitric oxide in end-stage renal disease: impact of inflammation, oxidative stress and haemodialysis.Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function.Symmetric dimethylarginine (SDMA) serum levels in rheumatoid arthritis: correlations with insulin resistance and disease activity scores.

P2860

Q24338511-837C5AB3-2ECE-4E6A-9772-323BFA394662 Q26864318-81AFE300-F453-4216-9F7B-D50BAAB55955 Q28485286-CD55C229-69C1-497C-8056-DF170BA29DA7 Q34556614-043D4ACD-6037-44C1-8C92-C7A85F469C56 Q34950263-844990F6-1B3B-4C74-82DF-BF5497EE115F Q35607229-4C8DEB65-AD91-4311-A90A-76C0632241A7 Q35686992-FCA771EE-A648-46BD-90C9-45FF266015F5 Q35985806-8FF995BC-3471-4DC9-B4AC-810D76690A73 Q36182184-25159A3F-952B-4463-B061-6898480C4905 Q36205262-FC124EB8-5E3A-4494-BD37-8B74AAB0004E Q36498512-3E1C46B9-8983-45B2-863E-D10E4C95A11C Q36509293-CF6DB1C9-621E-4829-AD38-5BDCB8E81D82 Q36694184-6F9C7C72-6E4D-4278-8A24-92DE1BB0EBCD Q36701882-EDF95CC7-907D-4DB0-900B-CA4AE0E2EC6E Q37260269-B4EE2C69-2B0A-45BF-AF27-8C7E60893B79 Q37338551-6005DAD4-AC81-4855-80C5-BF73361BDF2F Q37612222-FB1E0EAB-164D-4A75-AC9F-865D77A5502F Q37704715-2F35B671-C2E6-4D0D-AFF9-6694269812C6 Q37727924-BDD244F5-AAA5-463C-A144-39CCFE17C3E2 Q37858880-F70FCEFB-97B8-4BEF-BC50-C3C02E830D1A Q38188010-18E827F1-271D-403A-8E3F-85D96481A522 Q38203518-1A907434-3B0D-44D3-9D37-5E1FBD84F668 Q39491072-6ABF9824-94FE-45FB-96C2-8C404CB0F34F Q39535124-71924D3C-D65F-4B32-9BF6-BB7ACA469AA1 Q40380245-24708761-4710-4FFB-A881-7BECA1B25DA2 Q40760252-47C1C97C-7709-455E-9424-7B00B2D5CC8F Q42535395-FA8EE2C6-C66A-43BD-A912-A96BE6B2DD0B Q42963654-9EA36DF6-F3EC-45C3-AD18-BC0BFA3DBE73 Q43949655-CAA75F52-4C73-46E8-933F-432E8C3E1B18 Q46343358-BB0DEBA0-9525-4DCF-8900-7D92225026FB Q49025803-D0A1FA20-D5EB-4747-9893-151B769018C0 Q53583233-6937032C-8005-4A09-8C3A-C9C3C3B49635

P2860

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

http://www.wikidata.org/entity/Q43287699

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en-gb

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@nl

type

label

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en-gb

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@nl

prefLabel

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en-gb

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@nl

P1433

Q43287699-1129DF95-17F4-4B26-91D5-A1DA21C20A9D

P1476

Q43287699-59F670F0-1758-437A-AD7C-942696247EB3

P2093

Q43287699-14E2F0A1-8E6F-45F9-A78C-75D15BD8FAB5

Q43287699-32587F8D-0FA2-4951-9897-2E83B1B47B84

Q43287699-521B74B7-238C-49BB-AC76-946FDDF639C2

Q43287699-67477A57-E9FF-4A48-A99C-5CDE6AD2CF1B

Q43287699-6B03FD06-C64C-4828-B0C6-CF358F4E773F

Q43287699-7A8A853E-D430-4222-ABA8-2EFB4AD66600

Q43287699-954A5C3D-D7BE-4735-9097-787C0FF4B363

Q43287699-CF80224F-ED8E-49BA-83D1-272592D36419

Q43287699-E912AFDA-8CC9-45F9-9F5C-F312428C9C14

P304

Q43287699-3CFD2046-7046-48DD-AFFA-5F1600479989

P31

Q43287699-021FB55E-A2CF-4D4D-93A0-36EDDEF565A1

P356

Q43287699-E9CBEEA4-400A-43EA-A946-1AA265D67418

P433

Q43287699-BC72C058-E355-483B-8C42-E4391058639D

P478

Q43287699-EB4182CF-E89F-4038-8B05-D73305F51540

P50

Q43287699-2E24EBC6-E96A-470B-99D2-85FACA44F450

Q43287699-A173E8C4-F775-4658-B29B-50629674DC43

P577

Q43287699-83BC009B-B9E8-4117-8338-680E6152477E

P698

Q43287699-AA5008BF-7DE1-44E3-AA61-99634419FFF7

P356

J.ATHEROSCLEROSIS.2009.06.039

P1433

Atherosclerosis

P1476

Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.

@en

P2093

Angela M Carter

http://www.w3.org/2001/XMLSchema#string

Dorothee Atzler

http://www.w3.org/2001/XMLSchema#string

Edzard Schwedhelm

http://www.w3.org/2001/XMLSchema#string

Friedrich Schulze

http://www.w3.org/2001/XMLSchema#string

Peter J Grant

http://www.w3.org/2001/XMLSchema#string

Rainer H Böger

http://www.w3.org/2001/XMLSchema#string

Ramzi Ajjan

http://www.w3.org/2001/XMLSchema#string

Renke Maas

http://www.w3.org/2001/XMLSchema#string

Rouven-Alexander von Holten

http://www.w3.org/2001/XMLSchema#string

P304

518-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ATHEROSCLEROSIS.2009.06.039

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

208

http://www.w3.org/2001/XMLSchema#string

P50

Edzard Schwedhelm

P577

2009-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19700158

http://www.w3.org/2001/XMLSchema#string